Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: John Zwiener who wrote (5287)	7/7/1998 7:43:00 AM
From: Rocketman	Read Replies (2) \| Respond to of 9719

John, while we haven't discussed them much lately, we do have Aurora (ABSC) in the model and V1 and I have thought for quite some time that it is pretty damn undervalued. As far as IGEN goes, I've been remiss in looking at it. Partly I think because we don't have much buy power right now, and I had been getting into hunker down mode, but I'm starting to come out of the blast shelter and look around a bit more. I'm adding IGEN to my portfolio list and I'll at least start watching it. Now, after a quick look at some IGEN stats, I don't get it, why are you so hot on them, the $600M market cap doesn't look that cheap to me with only $13.4M in sales (declining from prior year) and an $11.8M loss? Plus, what's the deal on the lawsuit(s)? Do you see the product sales rampups that are going to justify this market cap, or what??? I contrast that with ABSC who has only a $137M cap, $17M in "sales", and only lost $2.5M (trailing 12 month), and is the hot genomics area as opposed to the brutal diagnostics business. Is the IGEN diagnostics system that far advanced that it should demand this much premium, or am I missing something here??? Probably would help if I pulled up the 10K, but it is 4:40AM here and I'm going to bed! Rocketman